Department of Ophthalmology, Cantonal Hospital of Lucerne, CH-6000, Lucerne 16, Switzerland.
Medignition AG, Zurich, Switzerland.
Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2363-2371. doi: 10.1007/s00417-021-05202-3. Epub 2021 Apr 26.
The two glaucoma drainage devices (GDD) Ahmed and Baerveldt tubes are most commonly used for the treatment of refractory glaucoma. We noticed a significant number of patients with postoperative motility disorders resulting in diplopia. We investigated the occurrence and patterns of postoperative motility disorders overall and between the two GDD tubes using the Hess Screen Test.
Retrospective single-center matched case series of 20 patients undergoing Ahmed and 20 patients undergoing Baerveldt tube implantation with a follow-up of at least 1 year. In order to investigate the dynamic of GDD-induced motility disorder over time, from 25 patients, a follow-up examination from two different time periods (3 to 6 months and 12 to 24 months postoperatively) was available. From these 25 patients, 12 had received an Ahmed and 13 a Baerveldt GDD. To compare the different Hess Screen Tests, we developed nine categories of possible emerging motility disorder in the operated eye as a primary endpoint: Motility restriction in up-gaze, in down-gaze, in abduction, in adduction; combined motility disorders in up-gaze and adduction, up-gaze and abduction, down-gaze and adduction, down-gaze and abduction. If there was no motility disorder, this was also separately classified.
Regardless of the used device, Ahmed or Baerveldt, most patients experienced motility disorders to some extent; mainly down-gaze and adduction were affected. However not every motility disorder resulted in diplopia. Although over time a decrease in ocular misalignment was seen, the incidence of diplopia was stable. Nevertheless, only few required therapy. We noted no difference between Ahmed and Baerveldt tube implant devices.
Ocular misalignment and restriction of motility is a common finding after GDD. Although not every motility disorder results in diplopia, it is frequent. Therefore, it needs to be taken into consideration in informed consent.
两种青光眼引流装置(GDD)Ahmed 和 Baerveldt 引流管最常用于治疗难治性青光眼。我们注意到大量术后出现眼球运动障碍的患者出现复视。我们使用 Hess 屏幕测试调查了两种 GDD 管之间以及总体上的术后眼球运动障碍的发生和模式。
回顾性单中心匹配病例系列研究,包括 20 例接受 Ahmed 引流管植入和 20 例接受 Baerveldt 引流管植入的患者,随访时间至少为 1 年。为了研究 GDD 引起的眼球运动障碍随时间的动态变化,从 25 例患者中获得了两个不同时间段(术后 3 至 6 个月和 12 至 24 个月)的随访检查。这 25 例患者中,12 例接受了 Ahmed 引流管植入,13 例接受了 Baerveldt 引流管植入。为了比较不同的 Hess 屏幕测试,我们将手术眼可能出现的 9 种运动障碍分类为主要终点:上转运动受限、下转运动受限、外展运动受限、内收运动受限;上转和内收、上转和外展、下转和外展、下转和内收的联合运动障碍;如果没有眼球运动障碍,也单独分类。
无论使用何种装置(Ahmed 或 Baerveldt),大多数患者都在不同程度上出现了眼球运动障碍,主要是下转和内收运动受限。然而,并非每个眼球运动障碍都会导致复视。尽管随着时间的推移,眼位偏斜有所减少,但复视的发生率保持稳定。然而,只有少数患者需要治疗。我们没有发现 Ahmed 和 Baerveldt 引流管植入装置之间的差异。
GDD 后眼球运动障碍和运动受限是常见的发现。尽管并非每个眼球运动障碍都会导致复视,但它很常见。因此,在知情同意中需要考虑到这一点。